AstraZeneca drops BCMA drug after seeing early clinical data

AstraZeneca has stopped development of its anti-BCMA antibody-drug conjugate (ADC) in multiple myeloma. The Anglo-Swedish drugmaker was set to take MEDI2228 into phase 2 this year but has opted against forging ahead in the congested BCMA space.